Fibrocor Therapeutics develops disease-modifying therapeutics for fibrosis by utilizing a patient-derived target discovery platform that analyzes clinically annotated biorepositories of fibrotic tissue. The company addresses the high mortality rates associated with fibrosis-related diseases by identifying novel therapeutic targets and advancing promising drug candidates through pre-clinical assessment.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Fibrosis, characterized by excessive scar tissue formation, contributes to nearly 45% of deaths in the industrialized world, encompassing conditions like pulmonary fibrosis, liver cirrhosis, and chronic kidney disease. Current treatment options are limited, and late-stage prognosis remains poor due to the heterogeneity of fibrotic diseases.
Solution
Fibrocor Therapeutics is developing novel therapeutics for fibrosis by leveraging a patient-derived target discovery platform. The platform analyzes clinically annotated biorepositories of fibrotic tissue, including kidney, liver, and lung biopsies linked to longitudinal medical records, to identify and drug critical pathways in the fibrogenic process. By focusing on patient-derived insights, Fibrocor aims to identify novel disease targets and advance promising drug candidates through pre-clinical assessment, addressing the unmet need for effective fibrosis treatments. The approach combines a patient-derived target discovery platform with medicinal chemistry capabilities to develop first-in-class therapeutics.
Target Audience
Fibrocor's primary focus is on patients suffering from fibrotic diseases, and their work targets pharmaceutical companies and research institutions seeking novel therapeutic approaches for these conditions.
Features
- Access to a large fibrosis tissue biobank containing kidney, liver, and lung biopsies.
- Longitudinal biobank samples correlated with fibrotic pathology and clinical outcomes.
- Single-cell and bulk RNAseq analysis for target discovery.
- Focus on novel tractable fibrosis molecular pathways, genomic association, and key biological insights.
- Clinically relevant *in vitro* fibrosis assays and *in vivo* disease models for validating key candidate compounds.
- Identification of best-in-class drug candidates (FIB991, FIB992, and FIB918) ready to progress to the clinical phase.